GlassScriptPhysician profile
Beatriz Dinh
NPI 1649897687
$1,071.94
in general payments reported to CMS, 2019-2025
15 companies · $928 in 2025
The $928 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $144 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.21 | 2024-2025 | |
| Pfizer INC. | $158.69 | 2024-2025 | |
| Ucb, INC. | $118.02 | 2024-2025 | Rystiggo, Zilbrysq |
| Biogen, INC. | $110.90 | 2025 | Skyclarys, Spinraza, Qalsody |
| Novartis Pharmaceuticals Corporation | $100.38 | 2025 | |
| Genentech USA, INC. | $97.92 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Tg Therapeutics, INC. | $84.32 | 2025 | |
| Merz Pharmaceuticals, LLC | $55.33 | 2025 | Xeomin, Inbrija, Ampyra |
| Lundbeck LLC | $43.34 | 2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $41.41 | 2025 | Ultomiris |
| Argenx US, INC. | $23.25 | 2025 | Vyvgart Hytrulo |
| Lilly USA, LLC | $17.92 | 2025 | Amyvid, Kisunla |
| Teva Pharmaceuticals USA, INC. | $17.85 | 2025 | Austedo Xr |
| Amgen INC. | $16.68 | 2025 | Uplizna |
| Alnylam Pharmaceuticals INC. | $14.72 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatriz Dinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.